KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Deferred Taxes (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Deferred Taxes for 16 consecutive years, with $613000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes fell 98.55% year-over-year to $613000.0, compared with a TTM value of $48.7 million through Dec 2025, down 13.12%, and an annual FY2025 reading of $48.7 million, down 13.12% over the prior year.
  • Deferred Taxes was $613000.0 for Q4 2025 at Biomarin Pharmaceutical, up from -$13.6 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $42.4 million in Q4 2024 and bottomed at -$51.3 million in Q4 2022.
  • Average Deferred Taxes over 5 years is -$392100.0, with a median of -$530000.0 recorded in 2022.
  • The sharpest move saw Deferred Taxes plummeted 1330.99% in 2022, then soared 9875.09% in 2025.
  • Year by year, Deferred Taxes stood at -$3.6 million in 2021, then tumbled by 1330.99% to -$51.3 million in 2022, then surged by 51.61% to -$24.8 million in 2023, then skyrocketed by 270.61% to $42.4 million in 2024, then tumbled by 98.55% to $613000.0 in 2025.
  • Business Quant data shows Deferred Taxes for BMRN at $613000.0 in Q4 2025, -$13.6 million in Q3 2025, and $33.3 million in Q2 2025.